n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Market Wrap: Stocks Bounce Back

The S&P 500 volatility index fell more than 16%.

3 High-Volume Stocks to Trade Now (or Not)

3 High-Volume Stocks to Trade Now (or Not)

Here's a technical look at some of the most active stocks on the market today.

Perilous Reversal Stock: ARIAD Pharmaceuticals (ARIA)

Perilous Reversal Stock: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

Market Wrap: Wild Week Ends With Whimper

Energy names fare well.

Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)

Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

ARIAD Pharmaceuticals (ARIA) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

ARIAD Announces First Patient Treated In Phase 2 Dose-Ranging Optic Trial Of Iclusig (Ponatinib)

ARIAD Announces First Patient Treated In Phase 2 Dose-Ranging Optic Trial Of Iclusig (Ponatinib)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the first patient has been treated in its OPTIC ( Optimizing Ponatinib Treatment In CML) trial of Iclusig ® (ponatinib).

ARIAD Reports Second Quarter 2015 Financial Results And Progress On Strategic Objectives

ARIAD Reports Second Quarter 2015 Financial Results And Progress On Strategic Objectives

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today reported financial results for the second quarter of 2015, including revenue from sales of Iclusig ® (ponatinib).

Perilous Reversal Watch: ARIAD Pharmaceuticals (ARIA)

Perilous Reversal Watch: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

ARIAD To Receive Up To $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing With PDL BioPharma

ARIAD To Receive Up To $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing With PDL BioPharma

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will receive $100 million in cash - $50 million upon deal execution late yesterday and an additional $50 million in one year - through a...

ARIAD Pharmaceuticals (ARIA) Flagged As Strong On High Volume

ARIAD Pharmaceuticals (ARIA) Flagged As Strong On High Volume

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

ARIAD To Webcast Conference Call On Second Quarter 2015 Financial Results

ARIAD To Webcast Conference Call On Second Quarter 2015 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2015 financial results on Wednesday, August 5, 2015, before the market opens.

ARIAD Pharmaceuticals is Now Oversold (ARIA)

ARIAD Pharmaceuticals is Now Oversold (ARIA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ARIA: Insiders vs. Shorts

ARIA: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 06/15/2015 settlement date, and ARIAD Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 15.71 "days to cover" versus the median component at 6.58.

First Week of February 2016 Options Trading For ARIAD Pharmaceuticals (ARIA)

First Week of February 2016 Options Trading For ARIAD Pharmaceuticals (ARIA)

Investors in ARIAD Pharmaceuticals, Inc. saw new options become available this week, for the February 2016 expiration.

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with...

ARIAD And Paladin Announce Commercial Distribution Agreement For Iclusig (Ponatinib) In Canada

ARIAD And Paladin Announce Commercial Distribution Agreement For Iclusig (Ponatinib) In Canada

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Paladin Labs Inc.

ARIAD To Present At The Goldman Sachs Annual Global Healthcare Conference

ARIAD To Present At The Goldman Sachs Annual Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Goldman Sachs Annual Global Healthcare Conference being held in Rancho Palos Verdes, CA.

ARIAD Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer At The 2015 ASCO Meeting

ARIAD Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer At The 2015 ASCO Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib ( AP26113 ), in patients with anaplastic lymphoma kinase positive...

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow-up data from the Phase 1 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant...

ARIAD To Present At The Jefferies 2015 Global Healthcare Conference

ARIAD To Present At The Jefferies 2015 Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City.

Revealed: The Best Ideas From 13F Filings

I am tracking smaller investors who are piling up big gains.

ARIAD Announces Data Presentations At The 2015 ASCO Annual Meeting

ARIAD Announces Data Presentations At The 2015 ASCO Annual Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig ® (ponatinib) and brigatinib (AP26113), its investigational anaplastic lymphoma kinase inhibitor, will be presented at the...

ARIAD Reports First Quarter 2015 Financial Results And Progress On Strategic Objectives

ARIAD Reports First Quarter 2015 Financial Results And Progress On Strategic Objectives

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the first quarter of 2015, including revenue from sales of Iclusig ® (ponatinib).

ARIAD Announces Commercial Distribution Agreement For Iclusig (ponatinib) In Turkey

ARIAD Announces Commercial Distribution Agreement For Iclusig (ponatinib) In Turkey

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Gen Ilac, a leading Turkish pharmaceutical company focused on the supply of orphan drugs for the treatments of rare diseases, today announced that ARIAD has granted Gen...

Strong On High Volume: ARIAD Pharmaceuticals (ARIA)

Strong On High Volume: ARIAD Pharmaceuticals (ARIA)

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

Ariad Pharma CEO 'Retires' in Settlement With Activist Hedge Fund

Ariad Pharma CEO 'Retires' in Settlement With Activist Hedge Fund

Sarissa Capital, which owns almost 7% of Ariad, started a proxy fight last February to wrest control of the board and force Berger's ouster.

ARIAD Enters Into Settlement Agreement With Sarissa Capital Management

ARIAD Enters Into Settlement Agreement With Sarissa Capital Management

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it has reached an agreement to settle its current proxy contest with Sarissa Capital Management.

ARIAD Founder, Harvey J. Berger, M.D., To Retire As Chairman And Chief Executive Officer

ARIAD Founder, Harvey J. Berger, M.D., To Retire As Chairman And Chief Executive Officer

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that its founder, Harvey J.

ARIAD Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today

ARIAD Pharmaceuticals (ARIA) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate